Review Articles

Timing and Targeting of Treatment in Left Ventricular Hypertrophy



In most clinical cases, left ventricular hypertrophy (LVH) occurs over time from persistent cardiac stress. At the molecular level, this results in both transient and long-term changes to metabolic, sarcomeric, ion handling, and stress signaling pathways. Although this is initially an adaptive change, the mechanisms underlying LVH eventually lead to maladaptive changes including fibrosis, decreased cardiac function, and failure. Understanding the regulators of long-term changes, which are largely driven by transcriptional remodeling, is a crucial step in identifying novel therapeutic targets for preventing the downstream negative effects of LVH and treatments that could reverse or prevent it. The development of effective therapeutics, however, will require a critical understanding of what to target, how to modify important pathways, and how to identify the stage of pathology in which a specific treatment should be used.


gene regulationtranscriptionleft ventricular hypertrophymolecular cardiac control
  • Year: 2017
  • Volume: 13 Issue: 1
  • Page/Article: 9-14
  • DOI: 10.14797/mdcj-13-1-9
  • Published on 1 Jan 2017
  • Peer Reviewed